İsa Döngel1, Ali Akbaş2, İsmail Benli3, Mehmet Bayram4. 1. Department of Thoracic Surgery, Süleyman Demirel University Medical Faculty, Isparta, Turkey. 2. Department of Clinical Biochemistry, Ataturk State Hospital, Balıkesir, Turkey. 3. Department of Clinical Biochemistry, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey. 4. Department of Chest Disease, Medipol University Faculty of Medicine, Istanbul, Turkey.
Abstract
BACKGROUND: In this study, we aimed to compare serum biochemical markers in patients with malignant pleural mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. METHODS: Between September 01, 2010 and March 31, 2011, a total of 540 participants (354 males, 186 females; mean age 61.4 years; range, 35 to 89 years) were included in the study. The participants were divided into four groups as follows: (1) patients with pleural plaques (n=277); (2) healthy individuals with normal chest X-rays who were exposed to environmental asbestos (n=121); (3) healthy individuals with normal chest X-rays who were not exposed to environmental asbestos (n=118); and (4) patients with malignant pleural mesothelioma (n=24). Serum levels of carcinoembryonic antigen, cancer antigen 125, 15-3, 19-9, free T3, free T4, thyroidstimulating hormone, vitamin B12, folate, and ferritin were measured. RESULTS: Serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels were higher with lower free T3 levels in Group 4 than the other groups. The areas under the curve for cancer antigen 125 and 15-3 were 0.78 and 0.67, respectively in the differential diagnosis of mesothelioma from other pathologies (p<0.001 for both). Optimal limits of these biomarkers were 13.63 and 18.43 ng/mL, respectively with 83% and 75% sensitivity and 69% and 48% specificity, respectively. CONCLUSION: The combination or individual use of serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels may be helpful for early diagnosis and treatment of malignant pleural mesothelioma.
BACKGROUND: In this study, we aimed to compare serum biochemical markers in patients with malignant pleural mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. METHODS: Between September 01, 2010 and March 31, 2011, a total of 540 participants (354 males, 186 females; mean age 61.4 years; range, 35 to 89 years) were included in the study. The participants were divided into four groups as follows: (1) patients with pleural plaques (n=277); (2) healthy individuals with normal chest X-rays who were exposed to environmental asbestos (n=121); (3) healthy individuals with normal chest X-rays who were not exposed to environmental asbestos (n=118); and (4) patients with malignant pleural mesothelioma (n=24). Serum levels of carcinoembryonic antigen, cancer antigen 125, 15-3, 19-9, free T3, free T4, thyroidstimulating hormone, vitamin B12, folate, and ferritin were measured. RESULTS: Serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels were higher with lower free T3 levels in Group 4 than the other groups. The areas under the curve for cancer antigen 125 and 15-3 were 0.78 and 0.67, respectively in the differential diagnosis of mesothelioma from other pathologies (p<0.001 for both). Optimal limits of these biomarkers were 13.63 and 18.43 ng/mL, respectively with 83% and 75% sensitivity and 69% and 48% specificity, respectively. CONCLUSION: The combination or individual use of serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels may be helpful for early diagnosis and treatment of malignant pleural mesothelioma.
Authors: Harvey I Pass; Stephen M Levin; Michael R Harbut; Jonathan Melamed; Luis Chiriboga; Jessica Donington; Margaret Huflejt; Michele Carbone; David Chia; Lee Goodglick; Gary E Goodman; Mark D Thornquist; Geoffrey Liu; Marc de Perrot; Ming-Sound Tsao; Chandra Goparaju Journal: N Engl J Med Date: 2012-10-11 Impact factor: 91.245
Authors: David T Arnold; Duneesha De Fonseka; Fergus W Hamilton; Najib M Rahman; Nick A Maskell Journal: Br J Cancer Date: 2017-02-07 Impact factor: 7.640